Authors:
Alajos PárUniversity of Pécs Department of Medicine Ifjúság u. 13 H-7643 Pécs Hungary

Search for other papers by Alajos Pár in
Current site
Google Scholar
PubMed
Close
,
István TornaiUniversity of Debrecen Department of Medicine Debrecen Hungary

Search for other papers by István Tornai in
Current site
Google Scholar
PubMed
Close
, and
Ferenc SzalaySemmelweis University Department of Medicine Budapest Hungary

Search for other papers by Ferenc Szalay in
Current site
Google Scholar
PubMed
Close
Restricted access

Introduction: In the past decade several multicentre, prospective, randomised trials have revealed a significant progress in the therapy for chronic viral hepatitis, but only limited and contradictory data are available regarding the real value of the antiviral treatment in the everyday routine clinical practice. Objective: A nation-wide retrospective analysis has been performed in order to assess the efficacy of antiviral therapy for patients with chronic hepatitis B and C representing the entire population that needed treatment in Hungary during a seven-year period. In addition, results of a prospective Hungarian study including patients with chronic hepatitis C are also presented. Patients and methods: A total of 220 patients with chronic hepatitis B treated with standard interferon-alpha (112), pegylated interferon-alpha-2a (23) or lamivudine (85) were investigated and the ratio of HBeAg seroconversion and/or undetectable HBV-DNA has been assessed. Of the 2442 patients with chronic hepatitis C, 333 were treated with standard interferon monotherapy, 1122 with standard interferon + ribavirin and 987 with pegylated interferon + ribavirin combination for 6 to 12 months. In a prospective study, 69 patients with chronic hepatitis C were enrolled and treated with pegylated interferon-alpha-2a + ribavirin. The rate of sustained virological response, the predictors of outcome and the adverse effects of treatment were evaluated. Results: For HBV patients standard IFN, PEG-IFN and lamivudine provided 31, 30, and 31 to 33% sustained virological response rate, respectively. In chronic hepatitis C, a continuous improvement was noted in sustained virological response, from 13% with interferon monotherapy to 31% with pegylated interferon + ribavirin combination, while even a 48% sustained virological response has been achieved in the prospective trial. The most important predictors of outcome were the 4-week ‘rapid’ and 12-week ‘early’ virological responses, then female gender, age, BMI and adherence. The most frequent complications of the treatment were cytopenia, haemolysis and depression, occurring in 9% of patients. Conclusion: Unlike in HBV infection, in chronic HCV hepatitis the efficacy of antiviral treatment has gradually improved in our everyday clinical practice, but the results are far poorer than those achieved in a prospective study. To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimalized, individualized dosing and novel antiviral agents.

  • World Health Organization. Hepatitis B fact sheet. WHO/204. Geneva: WHO, October 2000 (Accessed February 20, 2006, at http://www.who.int/mediacentre/factsheets/fs204/en )

  • Alberti, A.: Towards more individualized management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J. Hepatol., 2005, 42 , 266–274.

    Alberti A. , 'Towards more individualized management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels ' (2005 ) 42 J. Hepatol. : 266 -274 .

    • Search Google Scholar
  • Asselah, T., Ripault, M.-P., Castelnau, C. et al.: The current status of antiviral therapy of chronic hepatitis B. J. Clin. Virol., 2005, 34 , S115–S124.

    Castelnau C. , 'The current status of antiviral therapy of chronic hepatitis B ' (2005 ) 34 J. Clin. Virol. : S115 -S124 .

    • Search Google Scholar
  • Fehér J., Lengyel G.: Treatment of chronic hepatitis C. (In Hungarian). Orv. Hetil., 2004, 145 , 1065–1067.

    Lengyel G. , 'Treatment of chronic hepatitis C ' (2004 ) 145 Orv. Hetil. : 1065 -1067 .

    • Search Google Scholar
  • Pawlotsky, J.-M., McHutchison, J. G.: Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Hepatology, 2004, 39 , 554–567.

    McHutchison J. G. , 'Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls ' (2004 ) 39 Hepatology : 554 -567 .

    • Search Google Scholar
  • Paulon, E., Naumov, N. V.: Individualized treatment for chronic hepatitis C. (In Hungarian). Eur. J. Gastroenterol., Hepatol. (Hungarian edition), 2006, 10 , 173–177.

    Naumov N. V. , 'Individualized treatment for chronic hepatitis C ' (2006 ) 10 Eur. J. Gastroenterol., Hepatol. (Hungarian edition) : 173 -177 .

    • Search Google Scholar
  • Perrillo, R. P.: Therapy of hepatitis B – viral suppression or eradication? Hepatology, 2006, 43 , S182–S193.

    Perrillo R. P. , 'Therapy of hepatitis B – viral suppression or eradication? ' (2006 ) 43 Hepatology : S182 -S193 .

    • Search Google Scholar
  • Werling, K., Tulassay, Zs.: New trends in the treatment of patients with chronic hepatitis C. (In Hungarian). Orv. Hetil., 2006, 147 , 637–641.

    Tulassay Zs. , 'New trends in the treatment of patients with chronic hepatitis C ' (2006 ) 147 Orv. Hetil. : 637 -641 .

    • Search Google Scholar
  • Wright, T., Manns, M. P.: Therapy of hepatitis C – present and future. In: Boyer, T., Manns, M. P., Wright, T. (eds): Zakim and Boyers’ Hepatology: A Textbook of Liver Disease. 5th Ed. New York: Elsevier, 2006.

    Manns M. P. , '', in Zakim and Boyers’ Hepatology: A Textbook of Liver Disease , (2006 ) -.

  • Pár, A., Telegdy, L., Gógl, Á., et al.: Treatment of chronic viral hepatitis in Hungary. (In Hungarian). Orv. Hetil., 1999, 14 , 1227–1233.

    Gógl Á. , 'Treatment of chronic viral hepatitis in Hungary ' (1999 ) 14 Orv. Hetil. : 1227 -1233 .

    • Search Google Scholar
  • Tornai, I., Dalmi, L., Gervain, J. et al.: Treatment of patients with chronic hepatitis C using pegylated interferon alfa-2a and ribavirin. The first experiences in Hungary based upon a multicentric, open, prospective study. (In Hungarian). LAM, 2005, 15 , 807–813.

    Gervain J. , 'Treatment of patients with chronic hepatitis C using pegylated interferon alfa-2a and ribavirin. The first experiences in Hungary based upon a multicentric, open, prospective study ' (2005 ) 15 LAM : 807 -813 .

    • Search Google Scholar
  • McHutchison, J. G., Manns, M., Patel, K. et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 2002, 123 , 1061–69.

    Patel K. , 'Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C ' (2002 ) 123 Gastroenterology : 1061 -69 .

    • Search Google Scholar
  • Ferenci, P., Fried, M. W., Shiffman, M. L. et al.: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin. J. Hepatol., 2005, 43 , 425–433.

    Shiffman M. L. , 'Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin ' (2005 ) 43 J. Hepatol. : 425 -433 .

    • Search Google Scholar
  • Ferenci, P., Bergholz, U., Laferl, H. et al.: 24 week treatment regimen with peginterfon alfa-2a (40 kD) (PEGASYS) plus ribavirin (COPEGUS) in HCV genotype 1 or 4 “super-responders”. J. Hepatol., 2006, 44 (Suppl. 2) , S6.

    Laferl H. , '24 week treatment regimen with peginterfon alfa-2a (40 kD) (PEGASYS) plus ribavirin (COPEGUS) in HCV genotype 1 or 4 “super-responders” ' (2006 ) 44 J. Hepatol. : S6 -.

    • Search Google Scholar
  • Jensen, D. M., Morgan. T. R., Marcellin, P. et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a (40 kD)/ribavirin therapy. Hepatology, 2006, 43 , 954–960.

    Marcellin P. , 'Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a (40 kD)/ribavirin therapy ' (2006 ) 43 Hepatology : 954 -960 .

    • Search Google Scholar
  • Davis, G. L., Wong, J. B., McHutchison, J. G. et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38 , 645–652.

    McHutchison J. G. , 'Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C ' (2003 ) 38 Hepatology : 645 -652 .

    • Search Google Scholar
  • Hui, A. Z., Chan, H. L. Y., Cheung, A. Z.-K. et al.: Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment. Pharmacol. Ther., 2005, 22 , 519–528.

    Cheung A. Z.-K. , 'Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon ' (2005 ) 22 Aliment. Pharmacol. Ther. : 519 -528 .

    • Search Google Scholar
  • Chan, H. L.-Y., Hui, A. Z., Wong, V. W.-S. et al.: Long term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology, 2005, 41 , 1357–1364.

    Wong V. W.-S. , 'Long term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B ' (2005 ) 41 Hepatology : 1357 -1364 .

    • Search Google Scholar
  • Janssen, H. L. A., van Zonneveld, M., Senturk, H. et al.: Pegylated IFN alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis: a randomized trial. Lancet, 2005, 365 , 123–129.

    Senturk H. , 'Pegylated IFN alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis: a randomized trial ' (2005 ) 365 Lancet : 123 -129 .

    • Search Google Scholar
  • Marcellin, P., Lau, G. K. K., Bonino, F. et al.: Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med., 2004, 31 , 1206–1217.

    Bonino F. , 'Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B ' (2004 ) 31 N. Engl. J. Med. : 1206 -1217 .

    • Search Google Scholar
  • Liaw, Y. F., Leung, N. W., Chang, T. T. et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology, 2000, 119 , 172–180.

    Chang T. T. , 'Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B ' (2000 ) 119 Gastroenterology : 172 -180 .

    • Search Google Scholar
  • Leung, N. W., Lai, C. L., Chang, T. T. et al.: Extended lamivudine treatment in patients with hepatitits B enhances hepatitis e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 2001, 33 , 1527–1532.

    Chang T. T. , 'Extended lamivudine treatment in patients with hepatitits B enhances hepatitis e antigen seroconversion rates: results after 3 years of therapy ' (2001 ) 33 Hepatology : 1527 -1532 .

    • Search Google Scholar
  • Papatheodoridis, G. V., Dimou, E., Laras, A. et al.: Course of virologic breakthrough under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology, 2002, 36 , 219–226.

    Laras A. , 'Course of virologic breakthrough under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease ' (2002 ) 36 Hepatology : 219 -226 .

    • Search Google Scholar
  • Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J. et al.: Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med., 2005, 352 , 2673–2681.

    Heathcote E. J. , 'Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B ' (2005 ) 352 N. Engl. J. Med. : 2673 -2681 .

    • Search Google Scholar
  • Protocol for the treatment of chronic viral hepatititis. (In Hungarian). Orv. Hetil., 2006, 147, 2481–2484.

  • Chang, T.-T, Gish, R. G., Hadziyannis, S. J. et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine refractory chronic hepatitis B patients. Gastroenterology, 2005, 129 , 1198–1209.

    Hadziyannis S. J. , 'A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine refractory chronic hepatitis B patients ' (2005 ) 129 Gastroenterology : 1198 -1209 .

    • Search Google Scholar
  • Chang, T.-T., Gish, R. G., de Man, R. et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med., 2006, 354 , 1001–1010.

    Man R. , 'A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B ' (2006 ) 354 N. Engl. J. Med. : 1001 -1010 .

    • Search Google Scholar
  • Lai, C.-L., Shouval, D., Lok, A. S. et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med., 2006, 354 , 1011–1020.

    Lok A. S. , 'Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B ' (2006 ) 354 N. Engl. J. Med. : 1011 -1020 .

    • Search Google Scholar
  • Lim, S. G., Krastev, Z., Ng, T. M., et al.: Randomized, double-blind study of emtricitabine (FTC) plus lamivudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob. Agents Chemother., 2006, 50 , 1642–1648.

    Ng T. M. , 'Randomized, double-blind study of emtricitabine (FTC) plus lamivudine versus FTC alone in treatment of chronic hepatitis B ' (2006 ) 50 Antimicrob. Agents Chemother. : 1642 -1648 .

    • Search Google Scholar
  • Lee, H.-S., Chung, Y.-H., Lee, K. S. et al.: A 12 week clevudin therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2006, 43 , 982–988.

    Lee K. S. , 'A 12 week clevudin therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B ' (2006 ) 43 Hepatology : 982 -988 .

    • Search Google Scholar
  • Lai, C.-L., Leung, N., Teo, E.-K. et al.: A 1 year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology, 2005, 129 , 528–536.

    Teo E.-K. , 'A 1 year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B ' (2005 ) 129 Gastroenterology : 528 -536 .

    • Search Google Scholar
  • Ristig, M. B., Crippin, J., Aberg, J. A. et al.: Tenofovir disoproxil fumarate therapy for hepatitis B in human immunodeficiency virus/hepatitis B co-infected individuals for whom interferon alfa and lamivudine therapy have failed. J. Infect. Dis., 2002, 186 , 1844–1847.

    Aberg J. A. , 'Tenofovir disoproxil fumarate therapy for hepatitis B in human immunodeficiency virus/hepatitis B co-infected individuals for whom interferon alfa and lamivudine therapy have failed ' (2002 ) 186 J. Infect. Dis. : 1844 -1847 .

    • Search Google Scholar
  • Erhardt, A., Blondin, D., Hauck, K. et al.: Response to interferon alfa in hepatitis B genotype dependent: genotype A is more sensitive to IFN than genotype D. Gut, 2005, 54 , 1009–1013.

    Hauck K. , 'Response to interferon alfa in hepatitis B genotype dependent: genotype A is more sensitive to IFN than genotype D ' (2005 ) 54 Gut : 1009 -1013 .

    • Search Google Scholar
  • Fried, M. W., Shiffman, M. L., Reddy, K. R. et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347 , 975–982.

    Reddy K. R. , 'Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection ' (2002 ) 347 N. Engl. J. Med. : 975 -982 .

    • Search Google Scholar
  • Hadziyannis, S. J., Sette, H., Jr. Morgan, T. R. et al.: Peginterferon-alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomised study of treatment duration and ribavirin dose. Ann. Intern. Med., 2004, 140 , 346–355.

    Morgan T. R. , 'Peginterferon-alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomised study of treatment duration and ribavirin dose ' (2004 ) 140 Ann. Intern. Med. : 346 -355 .

    • Search Google Scholar
  • Manns, M. P., McHutchison, J. G., Gordon, S. C. et al.: Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358 , 958–65.

    Gordon S. C. , 'Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial ' (2001 ) 358 Lancet : 958 -65 .

    • Search Google Scholar
  • Scognamiglio, P., Cuzzi, G., Iezzi, L. et al.: Impact of treatment for hepatitis C infection in clinical practice. J. Hepatol., 2006, 44 (Suppl. 2) , S226.

    Iezzi L. , 'Impact of treatment for hepatitis C infection in clinical practice ' (2006 ) 44 J. Hepatol. : S226 -.

    • Search Google Scholar
  • Cozzolongo, R., Sartori, M., Lanzilotta, E. et al.: Comparison between the two peginterferons alfa in the treatment of chronic hepatitis C. J. Hepatol., 2006, 44 (Suppl. 2) , S209.

    Lanzilotta E. , 'Comparison between the two peginterferons alfa in the treatment of chronic hepatitis C ' (2006 ) 44 J. Hepatol. : S209 -.

    • Search Google Scholar
  • Dudley, T., O’Donnell, K., Haydon, G. et al.: Disappointing results of combination therapy for HCV? Gut, 2006, 55 , 1362–1363.

    Haydon G. , 'Disappointing results of combination therapy for HCV? ' (2006 ) 55 Gut : 1362 -1363 .

    • Search Google Scholar
  • Almasio, P. L., Cavalletto, L., Chemello, L. et al.: Efficacy of PEG-IFN alfa-2b vs PEG-IFN alfa-2a + ribavirin regimens in treatment-naive chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinical sites. Hepatology, 2005, 42 (Suppl. 1) , 671A.

    Chemello L. , 'Efficacy of PEG-IFN alfa-2b vs PEG-IFN alfa-2a + ribavirin regimens in treatment-naive chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinical sites ' (2005 ) 42 Hepatology : 671A -.

    • Search Google Scholar
  • Pálvölgyi, A., Nagy, I., Korom, T. et al.: Current results of pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy in patients with chronic hepatitis C. Z. Gastroenterol., 2006, 43 , 435.

    Korom T. , 'Current results of pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy in patients with chronic hepatitis C ' (2006 ) 43 Z. Gastroenterol. : 435 -.

    • Search Google Scholar
  • Zeuzem, S., Buti, M., Ferenci, P. et al.: Efficacy of 24 weeks treatment with peginterferon alfa-2a plus ribavirin in patients with hepatitis C infected with genotype 1 and low viremia. J. Hepatol., 2006, 44 , 97–103.

    Ferenci P. , 'Efficacy of 24 weeks treatment with peginterferon alfa-2a plus ribavirin in patients with hepatitis C infected with genotype 1 and low viremia ' (2006 ) 44 J. Hepatol. : 97 -103 .

    • Search Google Scholar
  • Berg, T., von Wagner, M., Nasser, S. et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alfa-2a plus ribavirin. Gastroenterology, 2006, 130 , 1086–1097.

    Nasser S. , 'Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alfa-2a plus ribavirin ' (2006 ) 130 Gastroenterology : 1086 -1097 .

    • Search Google Scholar
  • Sanchez-Tapias, J. M., Diago, M., Escartin, P. et al.: Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNS at week 4 of treatment. Gastroenterology, 2006, 131 , 451–460.

    Escartin P. , 'Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNS at week 4 of treatment ' (2006 ) 131 Gastroenterology : 451 -460 .

    • Search Google Scholar
  • Jensen, D., Andreone, P., Benhamou, Y. et al.: Safety of peginterferon alfa-2a (40 kD) (PEGASYS) plus ribavirin (COPEGUS) among pegylated interferon alfa-2a (12 kD) plus ribavirin non-responders: interim analysis of the REPEAT study. J. Hepatology, 2006, 44 (Suppl. 2) , S216.

    Benhamou Y. , 'Safety of peginterferon alfa-2a (40 kD) (PEGASYS) plus ribavirin (COPEGUS) among pegylated interferon alfa-2a (12 kD) plus ribavirin non-responders: interim analysis of the REPEAT study ' (2006 ) 44 J. Hepatology : S216 -.

    • Search Google Scholar
  • Nelson, D., Rustgi, V., Balan, V. et al.: A phase 2 study of albuferon in combination with ribavirin on non-responders to prior interferon for chronic hepatitis C. Hepatol., 2005, 42 (Suppl. 1) , 278.

    Balan V. , 'A phase 2 study of albuferon in combination with ribavirin on non-responders to prior interferon for chronic hepatitis C ' (2005 ) 42 Hepatol. : 278 -.

    • Search Google Scholar
  • Benhamou, Y., Pockros, P., Rodriguez-Torres, M. et al.: The safety and efficacy of viramidine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naive patients infected with HCV: phase 3 results. J. Hepatol., 2006, 44 (Suppl. 2) , S273.

    Rodriguez-Torres M. , 'The safety and efficacy of viramidine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naive patients infected with HCV: phase 3 results ' (2006 ) 44 J. Hepatol. : S273 -.

    • Search Google Scholar
  • Zeuzem, S., Sarrazin, C., Wagner, F. et al.: The HCV NS3 Protease inhibitor SCH 503034 in combination with PEG-IFN alfa-2b in the treatment of HCV-1 PEG-IFN alfa-2b non-responders: antiviral activity and HCV variant analysis. J. Hepatol., 2006, 44 (Suppl. 2) , S35.

    Wagner F. , 'The HCV NS3 Protease inhibitor SCH 503034 in combination with PEG-IFN alfa-2b in the treatment of HCV-1 PEG-IFN alfa-2b non-responders: antiviral activity and HCV variant analysis ' (2006 ) 44 J. Hepatol. : S35 -.

    • Search Google Scholar
  • Wedemeyer, H., Van Vlieberghe, H., Blum, H. et al.: E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: results of a 15-month, placebo-controlled trial. J. Hepatol., 2006, 44 (Suppl. 2) , S229.

    Blum H. , 'E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: results of a 15-month, placebo-controlled trial ' (2006 ) 44 J. Hepatol. : S229 -.

    • Search Google Scholar
  • Collapse
  • Expand
  • Top

Hungarian Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2022 0 0 0
May 2022 1 0 0
Jun 2022 0 0 0
Jul 2022 0 0 0
Aug 2022 0 0 0
Sep 2022 0 0 0
Oct 2022 1 0 0